Publication
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerGastric Carcinomacivic_curation1.00
- drugFexagratinibcivic_curation1.00
- geneFGFR1civic_curation1.00
- geneFGFR2civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
- variantFGFR2 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27179038
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR2 Amplification1 | ||||||||
| Fexagratinib | Gastric CarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1990Nine patients with FGFR2-amplified gastroesophageal cancer were treated with AZD4547. Of these 9 patients, 3 showed confirmed responses to AZD4547. Median progression-free survival was 6.6 months (ra… (full text at CIViC) PMID 27179038 · Pearson et al., 2016 · Open in CIViC | civic |
| FGFR1 Amplification1 | ||||||||
| Fexagratinib | HER2 Negative Breast CancerUNRESOLVED | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1991Eight patients with advanced HER2-negative breast cancer and FGFR1 amplification were evaluated for response to AZD4547. One patient (12.4%) demonstrated a confirmed response to AZD4547. In a preclini… (full text at CIViC) PMID 27179038 · Pearson et al., 2016 · Open in CIViC | civic |